Part 2 – MRI services for colorectal or hepatocellular carcinomas

<table cellspacing="0" cellpadding="0" style="width:438.65pt; border-collapse:collapse"><thead><tr><td colspan="3" style="width:427.95pt; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; page-break-after:avoid; line-height:12pt"><span style="font-size:10pt; font-weight:bold">Group I5 </span><span style="font-size:10pt; font-weight:bold">–</span><span style="font-size:10pt; font-weight:bold"> Magnetic Resonance Imaging</span></p></td></tr><tr><td colspan="3" style="width:427.95pt; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; page-break-after:avoid; line-height:12pt"><span style="font-size:10pt; font-weight:bold">Subgroup 21 – Scan of Body – for specified conditions</span></p></td></tr><tr><td style="width:57.1pt; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; page-break-after:avoid; line-height:12pt"><span style="font-size:10pt; font-weight:bold">Item</span></p></td><td style="width:274.45pt; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; page-break-after:avoid; line-height:12pt"><span style="font-size:10pt; font-weight:bold">Service</span></p></td><td style="width:75pt; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; page-break-after:avoid; line-height:12pt"><span style="font-size:10pt; font-weight:bold">Fee ($)</span></p></td></tr></thead><tbody><tr style="height:84.85pt"><td style="width:57.1pt; border-top:1.5pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; margin-bottom:3pt; line-height:115%; font-size:10pt"><span>63545</span></p></td><td style="width:274.45pt; border-top:1.5pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p class="tabletext" style="margin-top:3pt; margin-bottom:3pt; font-size:10pt; background-color:#ffffff"><span>MRI – multiphase scans of the liver</span><span> (including delayed imaging, if performed)</span><span> with a </span><span>contrast agent, </span><span>for characterisation or intervention planning</span><span>, in a patient with:</span></p><div style="margin-left:3.75pt; background-color:#ffffff"><p class="tabletext" style="margin-top:0pt; margin-left:21.25pt; margin-bottom:0pt; text-indent:-21.25pt; font-size:10pt"><span><span>(a)</span></span><span style="font:7pt 'Times New Roman'"> </span><span>known colorectal carcinoma; and</span></p></div><div style="margin-left:3.75pt; background-color:#ffffff"><p class="tabletext" style="margin-top:0pt; margin-left:21.25pt; margin-bottom:0pt; text-indent:-21.25pt; font-size:10pt"><span><span>(b)</span></span><span style="font:7pt 'Times New Roman'"> </span><span>known, suspected, or possible liver metastasis; and</span></p></div><div style="margin-left:3.75pt; background-color:#ffffff"><p class="tabletext" style="margin-top:0pt; margin-left:21.25pt; margin-bottom:0pt; text-indent:-21.25pt; font-size:10pt"><span><span>(c)</span></span><span style="font:7pt 'Times New Roman'"> </span><span>c</span><span>omputed tomography or ultrasound imaging have identified a mass lesion in the liver</span><span>.</span></p></div><p class="tabletext" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; background-color:#ffffff"><span>For</span><span> </span><span>any particular patient—</span><span>applicable not more than once in a 12 month period</span><span> (R) (K) (Anaes.)</span><span> (Contrast)</span></p></td><td style="width:75pt; border-top:1.5pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; margin-left:29.7pt; margin-bottom:3pt; page-break-after:avoid; line-height:115%; font-size:10pt"><span>550.00</span></p></td></tr><tr style="height:84.25pt"><td style="width:57.1pt; border-top:0.75pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; margin-bottom:3pt; line-height:115%; font-size:10pt"><span>63546</span></p></td><td style="width:274.45pt; border-top:0.75pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p class="tabletext" style="margin-top:3pt; margin-bottom:3pt; font-size:10pt; background-color:#ffffff"><span>MRI – multiphase scans of the liver</span><span> (including delayed imaging, if performed)</span><span> with a </span><span>contrast agent, </span><span>for </span><span>diagnosis or staging, in a patient with known or suspected hepatocellular carcinoma, and:</span></p><div style="margin-left:3.75pt; background-color:#ffffff"><p class="tabletext" style="margin-top:0pt; margin-left:21.25pt; margin-bottom:0pt; text-indent:-21.25pt; font-size:10pt"><span><span>(a)</span></span><span style="font:7pt 'Times New Roman'"> </span><span>chronic liver disease</span><span>,</span><span> that </span><span>has been</span><span> confirmed by a specialist</span><span> or consultant physician; and</span></p></div><div style="margin-left:3.75pt; background-color:#ffffff"><p class="tabletext" style="margin-top:0pt; margin-left:21.25pt; margin-bottom:0pt; text-indent:-21.25pt; font-size:10pt"><span><span>(b)</span></span><span style="font:7pt 'Times New Roman'"> </span><span>liver function identified as </span><span>Child-Pugh class A or B</span><span>; and</span></p></div><div style="margin-left:3.75pt; background-color:#ffffff"><p class="tabletext" style="margin-top:0pt; margin-left:21.25pt; margin-bottom:0pt; text-indent:-21.25pt; font-size:10pt"><span><span>(c)</span></span><span style="font:7pt 'Times New Roman'"> </span><span>an </span><span>identified hepatic lesion over 10</span><span> mm in diameter.</span></p></div><p class="tabletext" style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; background-color:#ffffff"><span>For</span><span> </span><span>any particular patient—</span><span>applicable not more than once in a 12 month period</span><span> (R) (K) (Anaes.)</span><span> (Contrast)</span></p></td><td style="width:75pt; border-top:0.75pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; margin-left:29.7pt; margin-bottom:3pt; page-break-after:avoid; line-height:115%; font-size:10pt"><span>550.00</span></p></td></tr></tbody></table>